BFLY Butterfly Network, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
BFLY Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$4.51
Analyst Target
$5.06
+12.3%
Upside
52W High
$5.03
52W Low
$1.32
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.14B
P/E
N/A
ROE
-41.4%
Profit margin
-90.3%
Debt/Equity
0.1
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
Butterfly Network (BFLY) shows a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a definitive bankruptcy risk assessment. Despite deeply negative profitability metrics—including a -90.31% profit margin and negative ROE/ROA—the company maintains strong liquidity (Current Ratio: 4.80) and a low Debt/Equity ratio of 0.10. Revenue growth is modest at 4.50% YoY, but earnings surprises have been consistently positive in recent quarters, suggesting operational improvements. However, aggressive insider selling worth $21.71M over the past six months contradicts the 'strong_buy' analyst consensus and raises concerns about insider confidence.
Key Strengths
Strong liquidity position with Current Ratio of 4.80 and Quick Ratio of 3.35
Low leverage with Debt/Equity ratio of 0.10, well below sector average of 2.28
High gross margin of 62.92%, indicating pricing power or efficient production
Consistently beats earnings estimates, with 3 out of last 4 quarters showing positive surprises averaging +35.24%
Significant short-term price momentum: +128.9% over 6 months and +14.2% in 1 month
Key Risks
Piotroski F-Score of 5 indicates borderline financial stability; not strong enough to signal robust health
Severe unprofitability: -90.31% profit margin and -41.42% ROE suggest ongoing fundamental weaknesses
Negative Forward P/E of -32.80 implies no near-term earnings recovery priced in
Massive insider selling: $21.71M in sales over 6 months with zero buys, signaling strong bearish sentiment from insiders
Lack of key financial data (e.g., total cash, debt, shares outstanding) limits transparency and increases investment risk
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
40
Moderate
35
55
60
52
0
AI Verdict
Cautiously Neutral – Mixed signals between improving operational execution and persistent profitability issues.
Key drivers: Positive earnings surprises and strong gross margin, High insider selling pressure, Low leverage and strong liquidity, Negative profitability and forward earnings
Confidence
70%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 12.88 may be justifiable if growth accelerates
Watchpoints
- Negative P/E and Forward P/E make valuation unreliable
- Price/Book of 5.59 is high given negative ROE
- No Graham Number available due to unprofitability
Future
55/100
Ref Growth rates
Positives
- Revenue growth of 4.50% YoY, though modest, shows positive trajectory
- Analyst target price of $5.06 implies 12% upside
Watchpoints
- No EBITDA or FCF data to assess sustainability of growth
- Forward P/E of -32.80 indicates no earnings growth expected in near term
Past
60/100
Ref Historical trends
Positives
- Consistent earnings beat rate: 3 out of last 4 quarters
- Average earnings surprise of +35.24% over last 4 quarters
- 6M return of +128.9% outperforms peers
Watchpoints
- 5Y total return of -76.9% reflects long-term underperformance
Health
52/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 5/9 indicates stable financial condition
- Strong liquidity with Current Ratio of 4.80
- Very low Debt/Equity of 0.10
Watchpoints
- No Altman Z-Score available limits distress risk analysis
- Negative ROA (-14.35%) and ROE (-41.42%) indicate poor asset and equity efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend program; Dividend Strength score of 0/100
- Payout ratio is 0.00% due to lack of profitability
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.51
Analyst Target
$5.06
Upside/Downside
+12.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BFLY and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BFLY
Butterfly Network, Inc.
Primary
|
-76.9% | +59.4% | +8.9% | +128.9% | +14.2% | +8.4% |
|
ALVO
Alvotech
Peer
|
-69.0% | -74.3% | -69.0% | -56.8% | -28.4% | -13.5% |
|
BLFS
BioLife Solutions, Inc.
Peer
|
-40.8% | -0.5% | -10.7% | +10.1% | -2.1% | +1.8% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-32.8
PEG Ratio
N/A
P/B Ratio
5.59
P/S Ratio
12.88
EV/Revenue
11.49
EV/EBITDA
-16.66
Market Cap
$1.14B
Profitability
Profit margins and return metrics
Profit Margin
-90.31%
Operating Margin
-69.69%
Gross Margin
62.92%
ROE
-41.42%
ROA
-14.35%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.1
Low debt
Current Ratio
4.8
Strong
Quick Ratio
3.35
Excellent
Cash/Share
$0.57
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-27
$N/A
2025-10-31
$-0.04
+20.0% surprise
2025-08-01
$-0.03
+42.9% surprise
2025-05-02
$-0.04
+42.9% surprise
Healthcare Sector Comparison
Comparing BFLY against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-41.42%
This Stock
vs
-52.77%
Sector Avg
-21.5%
(Below Avg)
Profit Margin
-90.31%
This Stock
vs
-20.78%
Sector Avg
+334.7%
(Superior)
Debt to Equity
0.1
This Stock
vs
6.16
Sector Avg
-98.3%
(Less Debt)
Revenue Growth
4.5%
This Stock
vs
137.39%
Sector Avg
-96.7%
(Slower)
Current Ratio
4.8
This Stock
vs
3.36
Sector Avg
+42.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BFLY
Butterfly Network, Inc.
|
NEUTRAL | $1.14B | - | -41.4% | -90.3% | $4.51 | |
|
ALVO
Alvotech
|
BEARISH | $1.08B | 15.09 | -% | 12.1% | $3.47 | |
|
BLFS
BioLife Solutions, Inc.
|
NEUTRAL | $1.2B | - | -5.2% | -3.2% | $24.87 | |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-08 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 1,140,180 | $4,695,583 |
| 2026-01-07 | DOHERTY JOHN N | Chief Financial Officer | Sale | 60,182 | $239,524 |
| 2026-01-05 | KU VICTOR | Chief Technology Officer | Sale | 35,968 | $137,398 |
| 2025-12-26 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 62,365 | $249,906 |
| 2025-12-16 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 886,294 | $2,796,489 |
| 2025-12-15 | PHANSTIEL S LOUISE | Director | Purchase | 185,261 | $571,160 |
| 2025-12-12 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 605,565 | $1,880,785 |
| 2025-12-11 | ROBBINS LARRY | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 21,370 | $64,471 |
| 2025-12-09 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 945,397 | $3,064,544 |
| 2025-12-08 | DOHERTY JOHN N | Chief Financial Officer | Stock Award | 1,294,870 | - |
| 2025-12-05 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 101,796 | $313,064 |
| 2025-12-05 | ROBBINS LARRY | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,558,541 | $4,652,773 |
| 2025-12-02 | CAEZZA NICHOLAS | General Counsel | Sale | 1,686 | $4,770 |
| 2025-11-28 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 132,570 | $408,183 |
| 2025-11-26 | ROTHBERG JONATHAN M | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 2,227,876 | $7,089,930 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
Lake Street
2026-01-20
Buy
Buy
Freedom Capital Markets
2025-12-31
Buy
Past News Coverage
Recent headlines mentioning BFLY from our newsroom.
Newest → oldest
No matching news yet.